Home > Insider Trading > Filing (0001567619-21-004514)

Filing Details

Accession Number:: 0001567619-21-004514
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-19 17:00:50
Reporting Period:: 2021-02-17

Accepted Time:: 2021-02-19 17:00:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556270	Jay Jonathan Mazelsky	One Idexx Drive Westbrook ME 04092	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-17	25,000	$52.00	68,090	No	4	M	Direct
Common Stock	Disposition	2021-02-17	3,940	$535.94	64,150	No	4	S	Direct
Common Stock	Disposition	2021-02-17	5,376	$536.78	58,744	No	4	S	Direct
Common Stock	Disposition	2021-02-17	3,069	$537.84	55,705	No	4	S	Direct
Common Stock	Disposition	2021-02-17	500	$538.83	55,205	No	4	S	Direct
Common Stock	Disposition	2021-02-17	300	$540.82	54,905	No	4	S	Direct
Common Stock	Disposition	2021-02-17	583	$542.08	54,322	No	4	S	Direct
Common Stock	Disposition	2021-02-17	100	$543.14	54,222	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2021-02-17	25,000	$0.00	25,000	$52.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
24,002		2023-12-04	No	4	M	Direct

Footnotes

Represents the weighted average price of the shares sold ranging from a low of $535.325 to a high of $536.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $536.33 to a high of $537.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $537.388 to a high of $538.12 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $540.218 to a high of $541.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $542.08 to a high of $542.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.